However, paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) complicates treatment in 18% (95%CI 16–21%) of patients, with percentages up to 50% in high risk groups (i.e., low CD4 counts and a short interval between starting anti-tuberculosis treatment and ART). The gene discussed is CD4; the disease is tuberculosis.